March 25, 2022 4:48pm

As I stated this a.m., “The alternating positive and negative closes defines the infection of sentiment as it doesn’t take much to bounce or depress the cell and gene therapy sector.”

Pre-open indications: 4 Hits, 3 MISS and 1 Pimp/Pump/Promote

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The metrics say it all … just the facts

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

The week in review …

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +153.76 points (+0.44%); the S&P closed UP +22.90 points (+0.51%) while the Nasdaq closed DOWN -22.54 points (-0.16%)

 

Henry’omics:

The Dow and S&P jumped as the Nasdaq dived as the cell and gene therapy sector fell negatively.

For the week, the S&P 500 and Nasdaq Composite are set to close at least 1% higher. The Dow is marginally higher week to date. <CNBC>

The Ukraine-Russia conflict will keep investors on edge over the weekend. Moscow signaled it was scaling back its ambitions in Ukraine to focus on territory claimed by Russian-backed separatists. <Reuters>

The consumer sentiment report by the University of Michigan showed consumers are more pessimistic now than during the pandemic, as a result of rising inflation, rising rates and the Russia-Ukraine war. The index came in at 59.4 in March, down from 84.9 in March 2021. <IBD>

Luckily, the CBOE volatility index, also known as the “fear gauge” fell to its lowest level since Feb. 10.

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Friday opened negative at 5 up/29 downs, 3 flats, stayed negative at the mid-day at 6/29, ending with a negative close of 7/28;
  • Thursday opened negative at 15 up/17 downs, 3 flats, flipped positive at the mid-day at 25/9 and 1 flat, ending with a positive close of 28/6 and 1 flat;
  • Wednesday opened negative at 8 up/26 downs, 1 flat, stayed negative at the mid-day at 16/18 and 1 flat, ending with a negative close of 6/28 and 1 flat;
  • Tuesday opened positive at 28 up/6 downs, 1 flat, stayed positive at the mid-day at 30/5 and 1 flat, ending with a positive close of 31/4;
  • Monday opened negative at 5 up/29 downs, 1 flat, stayed negative at the mid-day at 1/33 and 1 flat, ending with a negative close of 2/31 and 2 flats;

 

Pre-open Indications: 4 Hits < BUY: SELL:  Caribou Biosciences (CRBU -$0.29), Sangamo Therapeutics (SGMO -$0.17), uniQure NV (QURE -$0.59); SELL into Strength: Fate Therapeutics (FATE -$0.69)> 3 Miss < Alnylam Pharmaceuticals (ALNY +$0.11), Beam Therapeutics (BEAM -$0.65), Intellia Therapeutics (NTLA -$1.36)> 1 pimp/pump/promote < Biostage (BSTG +$0.44)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … (FIXX, CRBU and BLCM) added with 31 to date

 

Key Metrics:

  • Friday - Sector volume was LOW with 1 of the 7-upside having higher than the 3-month average volume with LOW volume of 2 of 28-downside having higher than the 3-month average volume;
  • Thursday - Sector volume was LOW with 4 of the 28-upside having higher than the 3-month average volume with LOW volume of 1 of 6-downside having higher than the 3-month average volume;
  • Wednesday - Sector volume was LOW with 2 of the 6-upside having higher than the 3-month average volume with LOW volume of 3 of 28-downside having higher than the 3-month average volume;
  • Tuesday - Sector volume was LOW with 6 of the 31-upside having higher than the 3-month average volume with LOW volume of 1 of 4-downside having higher than the 3-month average volume;
  • Monday - Sector volume was LOW with 1 of the 2-upside having higher than the 3-month average volume with LOW volume of 6 of 31-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was down -1.44% and the XBI was down -2.34%
  • Thursday, the IBB was up +1.39% and the XBI was up +2.13%
  • Wednesday, the IBB was down -2.52% and the XBI was down -2.40%
  • Tuesday, the IBB was up +1.90% and the XBI was up +3.58%
  • Monday, the IBB was down -1.34% and the XBI was down -3.41%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.76 points or -3.51% at 20.91
  • Thursday was down -1.90 points or -8.06% at 21.67
  • Wednesday was up +0.63 points or +2.75% at 23.45
  • Tuesday was down -0.59 points or -1.51% at 22.94
  • Monday was down -0.29 points or -1.21% at 23.58

 

Jumping with share pricing momentum (7 of 7):

  • Biostage (BSTG +$0.44 with 1,978 shares traded after being FLAT most of week),
  • Regenxbio (RGNX+$0.17 after Thursday’s +$1.90, Wednesday’s +$2.08, Wednesday’s +$0.13 and Tuesday’s +$0.69),
  • Alnylam Pharmaceuticals (ALNY +$0.11 after Thursday’s +$1.35, Wednesday’s -$1.48, Tuesday’s +$1.40 and Monday’s -$2.82),
  • Adverum Biotechnologies (ADVM +$0.07),
  • Chinook Therapeutics (KDNY +$0.06),
  • Bellicum Pharmaceuticals (BLCM +$0.05 post earnings report),
  • Voyager Therapeutics (VYGR +$0.01),

Hammered in today’s market (10 of 28):

  • CRISPR Therapeutics (CRSP -$2.26 after Thursday’s +$0.83, Wednesday’s -$3.93, Tuesday’s +$1.84 after Monday’s -$2.23),
  • Intellia Therapeutics (NTLA -$1.36 after Thursday’s +$1.77, Wednesday’s -$3.30, Tuesday’s +$3.48 and Monday’s-$2.37),
  • Sage Therapeutics (SAGE -$1.22),
  • BioLife Solutions (BLFS -$1.16 after Thursday’s -$0.15, Wednesday’s -$1.00 and Tuesday’s -$1.64),
  • Fate Therapeutics (FATE -$0.69 after Thursday’s +$1.74 and Wednesday’s -$0.96),
  • Beam Therapeutics (BEAM -$0.65 after Thursday’s +$1.90, Wednesday’s -$4.90, Tuesday’s +$2.55 and Monday’s -$3.98),
  • uniQure NV (QURE -$0.59) after Thursday’s +$0.59),
  • Global Blood Therapeutics (GBT -$0.41),
  • Vericel (VCEL -$0.33 after Thursday’s +$1.26, Wednesday’s +$0.77, Tuesday’s +$1.07 and Monday’s -$1.62),
  • Caribou Biosciences (CRBU -$0.29 after Thursday’s -$0.09),

 

March, Q1/2022:

  • Friday closed negative with 7 incliners and 28 decliners
  • Thursday closed positive with 28 incliners, 6 decliners and 1 flat
  • Wednesday closed negative with 6 incliners, 28 decliners and 1 flat
  • Tuesday closed positive with 31 incliners and 4 decliners
  • Monday closed negative with 2 incliners, 31 decliners and 2 flats

 

 

The BOTTOM LINE: TGIF, expectation after an alternately positive versus negative closes this week showed that (as I stated this a.m.) sentiment was infected by these daily closes.

Cell and gene stocks crashed on Friday after gaining Thursday after falling Wednesday to give back some gains after rising a day (Tuesday), as investors after feeling the upside and battling the sell options and risks of dramatic move to the upside after a Monday’s crash.

I am still maintaining,” Caution is in order.”

What and which go up, also slip down; it’s sector physiology as risks go both ways.

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are still “gamy” than even I thought – two (2) this week: FIXX and CRBU.

Earnings’ reporting coming:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.